Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection
Journal of Clinical Virology · 2023
DOI: 10.1016/j.jcv.2023.105378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Virology, 2023. Verfasst von Runal John Steve und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Virology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Hepatitis A, Hepatitis B, Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: HBsAg Next assay (HBsAgNx) claims improved detection of HBsAg. The aim was to investigate its performance in ascertaining HBsAg loss, ability to detect HBsAg in various phases of HBV infection, specificity and its amenability to in-house neutralization. METHODS: Analytical sensitivity was investigated using NIBSC standard (3rd WHO-IS). For clinical performance, out of 91,962 samples tested for HBsAg (Qual-II), 512 samples consisting of 170 cases with evidence of HBsAg loss during treatment (n = 116) and without treatment (n = 54), acute-hepatitis B (n = 90) and acute exacerbation of chronic-hepatitis B (n = 41), acute-hepatitis A (n = 24) and acute-hepatitis E (n = 9) positive, HIV-1 positive (n = 20), non-HBV, HAV and HEV related acute-hepatitis (n = 81) and HBsAg prozone (n = 14) as well as in-house neutralization (n = 63) were included. RESULTS: The calculated limit of detection (LOD) was 0.004 IU/mL. Of the 170 patients with apparent HBsAg loss, 18/116 (15.5%) among treated and 15/54 (27.7%) with spontaneous clearance were positive in HBsAgNx (p < 0.0001). Additionally, it detected HBsAg in 12/95 (12.6%) and 6/34 (17.6%) patients who were HBV DNA negative in treatment experienced and spontaneous clearance groups respectively (p < 0.001). The specificity of HBsAgNx was comparable to HBsAg Qual-II. The signal-intensity of HBsAgNx was significantly higher than HBsAg Qual-II across various phases of HBV infection and prozone samples. CONCLUSION: HBsAgNx significantly enhanced the accuracy of HBsAg detection without compromising the specificity in ascertaining HBsAg loss. The performance was superior in various phases of HBV infection including samples that exhibited prozone effect. Furthermore, it is amenable to cost-effective in-house neutralization to confirm low HBsAg levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Virology, Christian Medical College, Vellore, India.
- Department of Transfusion Medicine and Immuno-haematology, Christian Medical College, Vellore, India.
- Department of Hepatology, Christian Medical College, Vellore, India.
- Department of Clinical Virology, Christian Medical College, Vellore, India. Electronic address: fletchergj@cmcvellore.ac.in.
Zitieren
APA
Steve, R. J., Prakash, A., Ponnuvel, S., Dickson, C. J., Nandan, K., Singh, B., Sam, G. A., Goel, A., Zachariah, U. G., Eapen, C. E., Kannangai, R., Abraham, P., & Fletcher, G. J. (2023). Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection. Journal of Clinical Virology. https://doi.org/10.1016/j.jcv.2023.105378
Vancouver
Steve RJ, Prakash A, Ponnuvel S, Dickson CJ, Nandan K, Singh B, et al. Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection. Journal of Clinical Virology. 2023. doi:10.1016/j.jcv.2023.105378
BibTeX
@article{Steve2023,
author = {Steve, Runal John and Prakash, Arul and Ponnuvel, Suresh and Dickson, Calvin John and Nandan, Karthick and Singh, Bakthalal and Sam, Gift Ajay and Goel, Ashish and Zachariah, Uday George and Eapen, Chundamannil Eapen and Kannangai, Rajesh and Abraham, Priya and Fletcher, Gnanadurai John},
title = {Versatile performance edges of HBsAg Next assay in diagnosis and therapeutic monitoring of HBV infection},
journal = {Journal of Clinical Virology},
year = {2023},
doi = {10.1016/j.jcv.2023.105378}
}
EUVIMED